Besides, the results provided by Tumor Immune Dysfunction and Exclusion (TIDE) database (Jiang et al., 2018) indicated that KCNN4 has the moderate ability to predict clinical response of varying cancer cohorts treated with immunotherapy (Supplementary Figure S3), with 11 of the 21 immunotherapy-treated cohorts having an area under the receiver operating characteristic curve (AUC) greater than 0.5. Here, KCNN4 is linked to neoplasm.